California is currently home to 5613 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea
Recruiting
The primary purpose of this study is to evaluate the effectiveness of sivopixant, acetazolamide and SASS-001 in adults with sleep apnea with a central component.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/16/2025
Locations: Altman Clinical and Translational Research Institute (ACTRI), La Jolla, California
Conditions: Sleep Apnea
A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations
Recruiting
A dose range-finding study to assess the efficacy and safety of multiple dose levels of AZD8630 administered via a dry powder inhaler in adults with uncontrolled asthma at risk of exacerbations, receiving medium -to -high dose inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/16/2025
Locations: Research Site, Huntington Beach, California
Conditions: Asthma
A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk"
Recruiting
Approximately 150 patients with acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF) will be randomized at up to 40 sites. Patients will be randomly assigned to either Auxora or matching placebo. Study drug infusions will occur every 24 hours for five consecutive days for a total of five infusions.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: UCLA, Los Angeles, California
Conditions: Acute Kidney Injury
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: UCLA Hematology/Oncology - Westwood (Building 200 Suite 214), Los Angeles, California
Conditions: Multiple Myeloma
StrokeNet Thrombectomy Endovascular Platform
Recruiting
STEP is a Randomized, Multifactorial, Adaptive Platform trial that seeks to optimize the care of patients with acute ischemic stroke (AIS) due to large (LVO) or medium vessel occlusions (MVO).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: UCSD Health La Jolla, La Jolla, California
Conditions: Ischemic Stroke
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3)
Recruiting
This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on an anti PD-1 and an anti-CTLA-4 containing regimen (administered either as a combination regimen or in sequence) or who are not candidates for treatment with an anti-CTLA-4 therapy.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/16/2025
Locations: Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, California
Conditions: Advanced Melanoma
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
Recruiting
CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic lupus erythematosus (SLE) with or without lupus nephritis (LN), idiopathic inflammatory myopathies (IIM), and diffuse cutaneous systemic sclerosis (DcSSc).
Gender:
ALL
Ages:
17 years and above
Trial Updated:
06/16/2025
Locations: Keck School of Medicine of University of Southern California, Los Angeles, California
Conditions: Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
Recruiting
The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are: 1. Is SNK01 safe and tolerable when administered every 3 weeks for up to 1 year as an intravenous infusion 2. Can SNK01 administration improve cognitive assessment scores and biomarkers
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
06/16/2025
Locations: Behavioral Research Specialists, LLC, Glendale, California
Conditions: Moderate Alzheimer Disease
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Recruiting
The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: City of Hope Comprehensive Cancer Center, Duarte, California
Conditions: Relapsed and/or Refractory Multiple Myeloma
HYDRAFIL-D: HYDRogel Augmentation For Intervertebral Lumbar Discs
Recruiting
A multi-center, prospective, dual arm, randomized, controlled pivotal study to evaluate the safety and effectiveness of the ReGelTec HYDRAFIL™ System.
Gender:
ALL
Ages:
Between 22 years and 85 years
Trial Updated:
06/16/2025
Locations: Boomerang Healthcare (IPM Medical Group), Walnut Creek, California
Conditions: Degenerative Disc Disease (DDD)
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Recruiting
The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the activity of XP01.
Gender:
ALL
Ages:
12 months and above
Trial Updated:
06/16/2025
Locations: Children's Hospital of Los Angeles (Data Collection Only), Los Angeles, California
Conditions: Wilms Tumor, Rhabdoid Tumor, Malignant Peripheral Nerve Sheath Tumors, MPNST, Nephroblastoma, XPO1 Gene Mutation, Solid Tumor
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
Recruiting
The main purpose of the study is to evaluate the safety and tolerability of HRO761 and identify the recommended dose(s), i.e., the optimal safe and active dose of HRO761 alone or in combination with pembrolizumab or irinotecan that can be given to patients who have cancers with specific molecular alterations called MSIhi (Microsatellite Instability-high) or dMMR (Mismatch Repair Deficient) that might work best to treat these specific cancer types and to understand how well HRO761 is able to trea... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/16/2025
Locations: University of California LA, Los Angeles, California
Conditions: MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers